medigraphic.com
ISSN 1561-3070 (Electronic)

2021, Number 3

<< Back Next >>

Rev Cub Oftal 2021; 34 (3)

Toxoplasmic retinochoroiditis and the evolution of visual results in immunocompetent patients

Naranjo VBT, León SMA, Ramos LM

Language: Spanish
References: 16
Page: 1-16
PDF size: 401.08 Kb.


ABSTRACT

Objective: Determine the evolution of visual results in patients with active ocular toxoplasmosis.
Methods: An observational longitudinal prospective study was conducted of 101 immunocompetent patients with active ocular toxoplasmosis attending the Uveitis Service at Abel Santamaría General University Hospital from January 2012 to December 2018. The variables evaluated were injury location, size, number, episode, degree of inflammation, complications, post-treatment recurrence and best corrected visual acuity. Results were analyzed with absolute and relative frequencies, chi-square statistical association, the Mann-Whitney U or Kruskall Wallis tests, the Friedman test and the Wilcoxon signed-rank test.
Results: According to injury location, the lowest visual results were obtained in patients with zone I lesions, whereas the best results corresponded to zone III lesions. A better visual result evolution was achieved in patients with lesions smaller than or equal to a papillary diameter. A statistical difference was found between the various degrees of inflammation severity, with a tendency to an increase in best corrected visual acuity with the passing of time after treatment.
Conclusions: Visual improvement is achieved during the evolution of immunocompetent patients with active ocular toxoplasmosis.


REFERENCES

  1. Garweg JG. Ocular Toxoplasmosis: an Update. 2016 [acceso: 17/06/2020];233(4):534-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27116531/

  2. Honório de Azevedo M, Lucena Moura G, Nery Rossi Camilo E, Muccioli C, Faria e Arantes T. Visual function and macular architecture in patients with inactive zone 2 and 3 toxoplasmic retinochoroiditis. Arq Bras Oftalmol. 2015 [acceso: 17/06/2020];78(5):273-7. Disponible en: https://search.bvsalud.org/gim/resource/fr/lil-761522

  3. American Academy of Ophthalmology. Basic and Clinical Science Course 2019-2020. Uveítis and ocular inflammation. San Francisco: American Academy of Ophthalmology; 2019.

  4. Sánchez R, Sánchez L, Miranda A, Camejo L, Araujo L. La toxoplasmosis observada como un problema no resuelto. Rev Cubana Invest Bioméd. 2015 [acceso: 17/06/2020];35(11). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002016000300006

  5. Ambou Frutos I, Vilches Lescaille DC, Osorio Illas L. Toxoplasmosis ocular. En: Río Torres M, Fernández Argones L, Hernández Silva JR, Ramos López M. Oftalmología. Diagnóstico y tratamiento. La Habana: Editorial Ciencias Médicas; 2018 [acceso: 17/06/2020]. Disponible en: http://www.ecimed.sld.cu/2019/06/05/oftalmologia- diagnostico-y-tratamiento-2da-ed/

  6. Rubio Rodríguez CG, Rodríguez Gil R, Pérez Muñoz D, Kalitovics Nobregas N, Álvarez Reyes F. Toxoplasmosis ocular adquirida en nuestro medio. Arch Soc Canar Oftalmol. 2016 [acceso: 17/06/2020];27:55-62. Disponible en: http://sociedadcanariadeoftalmologia.com/wp-content/revista/revista-27/27sco14.pdf

  7. Facio Lince LA, López de Mesa C, de la Torre A. Toxoplasmosis ocular en Colombia: 10 años de aportes investigativos. Rev Soc Colomb Oftalmol. 2018 [acceso: 17/06/2020];51(1):16-28. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=7025785

  8. Smith JR, Ashander LM, Ma Y, Rochet E, Furtado JM. Model Systems for Studying Mechanisms of Ocular Toxoplasmosis. Methods Mol Biol. 2020;2071:297-321. DOI: https://doi.org/10.1007/978-1-4939-9857-9_17

  9. Borges Pérez SM, Pérez Borges E, Ayllapan SN, Díaz Reyes A, Bayarte Nodales EM. Comportamiento clínico serológico de la toxoplasmosis ocular. La Habana: Act Méd. 2017 [acceso: 17/06/2020];18(2). Disponible en: http://www.medigraphic.com/pdfs/actamedica/acm-2017/acm172f.pdf

  10. Naranjo Valladares BT, López Torres M, Moreno Domínguez JC, Acosta Rodríguez F. La uveítis, comportamiento clínico epidemiológico en Pinar del Río. Rev Cienc Méd. 2015 [acceso: 17/06/2020];19(2):[aprox. 9 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-31942015000200011

  11. Bustillo JL, Díaz JD, Pacheco IC, David C Gritz. Cuban Ocular Toxoplasmosis Epidemiology Study (COTES): incidence and prevalence of ocular toxoplasmosis in Central Cuba. BMJ. 2015;99(3):[aprox. 4 p.]. DOI: https://doi.org/10.1136/bjophthalmol-2014-305843

  12. Rosado García FM. Importancia y factibilidad del diagnóstico ambiental deToxoplasma gondii en Cuba. Rev Cubana Salud Públ. 2014 [acceso: 17/06/2020];40(2):286-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 34662014000200014

  13. Ozgonul C, Besirli CG. Recent Developments in the Diagnosis and Treatment of Ocular Toxoplasmosis. Ophthalmic Res. 2017 [acceso: 17/06/2020];57(1):1-12. Disponible en: https://www.karger.com/Article/Pdf/449169

  14. Foster CS, Vitale AT. Diagnosis and treatment of uveitis. Philadelphia: Jaypee Brothers Medical Publishers; 2013 [acceso: 17/06/2020]. Disponible en: http://www.jaypeebrothers.com

  15. Ukamaka CF, Afekhide EO, Malachi EE. Clinical features and risk factors of patients with presumed ocular toxoplasmosis. Nigeria J Ophthal Vis Res. 2016;11(1):48-53. DOI: https://doi.org/10.4103/2008-322X.180694

  16. Colombero D, Gasperi C, Ladeveze E, Ortiz A, Botto ME, Garasa G, et al. Toxoplasmosis Ocular: Manifestaciones clínicas en 93 pacientes. Arch Arg Oftalmol. 2013 [acceso: 17/06/2020];(6):[aprox. 8 p.]. Disponible en: https://www.researchgate.net/publication/308938853




2020     |     www.medigraphic.com